Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data
Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breas...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-06, Vol.18 (6), p.e0287382-e0287382 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0287382 |
|---|---|
| container_issue | 6 |
| container_start_page | e0287382 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Shin, Kwang-Hee Ah, Young-Mi Cha, Sang Hun Choi, Hye Duck |
| description | Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription. |
| doi_str_mv | 10.1371/journal.pone.0287382 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2826707053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A753191786</galeid><doaj_id>oai_doaj_org_article_b4abe50e986d40d09714de8695b127c8</doaj_id><sourcerecordid>A753191786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642t-e2b722acf3fb89443da9e5bc7f83e0134c8d36ef26f4e3ef0fa3a30ae433f0c83</originalsourceid><addsrcrecordid>eNqNk21r2zAQx83YWLtu32BshsHYXiTTg23Zr0bpngKFwp7eirN8ShQUK5Xkrfv2UxK3xKMvhkAyp9_9z3e6y7LnlMwpF_Td2g2-Bzvfuh7nhNWC1-xBdkobzmYVI_zh0fdJ9iSENSElr6vqcXbCBWeCcXGawQc_LGe7LTd9RA8qGteH3Om8cwoj3KBNN_kWosE-hvy3iau89Qgh5gp6hT5vIWCXuz5xYfA7W64smE3IO4jwNHukwQZ8Np5n2Y9PH79ffJldXn1eXJxfzlRVsDhD1grGQGmu27opCt5Bg2WrhK45EsoLVXe8Qs0qXSBHTTRw4ASw4FwTVfOz7OVBd2tdkGN1gmQ1qwQRKfVELA5E52Att95swP-RDozcG5xfSvDRKIuyLaDFkmBTV11BOtIIWnRYV03ZUib20d6P0YZ2g51KtfFgJ6LTm96s5NL9kpQwURa8TApvRgXvrgcMUW5MUGgt9OiG_Y8LVvKmoQl99Q96f3ojtYSUgem1S4HVTlSei5LThoq6StT8HiqtDjdGpV7SJtknDm8nDomJeBOXMIQgF9--_j979XPKvj5iVwg2roKzw77_pmBxAJV3IXjUd1WmRO5G4bYacjcKchyF5Pbi-IXunG57n_8FzNYEYQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2826707053</pqid></control><display><type>article</type><title>Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data</title><source>PLoS (Open access)</source><source>Full-Text Journals in Chemistry (Open access)</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Shin, Kwang-Hee ; Ah, Young-Mi ; Cha, Sang Hun ; Choi, Hye Duck</creator><creatorcontrib>Shin, Kwang-Hee ; Ah, Young-Mi ; Cha, Sang Hun ; Choi, Hye Duck</creatorcontrib><description>Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0287382</identifier><identifier>PMID: 37327237</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Age ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic drugs ; Antitumor agents ; Biology and Life Sciences ; Breast cancer ; Cancer patients ; Care and treatment ; Colony-stimulating factor ; Comorbidity ; Complications and side effects ; Cytotoxicity ; Docetaxel ; Drug approval ; Drug dosages ; Drug interaction ; Drug interactions ; Drug therapy ; Drug therapy, Combination ; Drugs ; Evaluation ; Food ; Granulocyte colony-stimulating factor ; Health insurance ; Immunotherapy ; Insurance ; Leukocytes (granulocytic) ; Matching ; Medical diagnosis ; Medicine and Health Sciences ; Neutropenia ; Patient outcomes ; Patients ; Pharmacovigilance ; Prescription drugs ; Regression analysis ; Regression models ; Safety and security measures ; Social Sciences ; Statistical analysis ; Surgery</subject><ispartof>PloS one, 2023-06, Vol.18 (6), p.e0287382-e0287382</ispartof><rights>Copyright: © 2023 Shin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Shin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Shin et al 2023 Shin et al</rights><rights>2023 Shin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c642t-e2b722acf3fb89443da9e5bc7f83e0134c8d36ef26f4e3ef0fa3a30ae433f0c83</cites><orcidid>0000-0003-2292-6827</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275435/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275435/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37327237$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Kwang-Hee</creatorcontrib><creatorcontrib>Ah, Young-Mi</creatorcontrib><creatorcontrib>Cha, Sang Hun</creatorcontrib><creatorcontrib>Choi, Hye Duck</creatorcontrib><title>Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.</description><subject>Age</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Biology and Life Sciences</subject><subject>Breast cancer</subject><subject>Cancer patients</subject><subject>Care and treatment</subject><subject>Colony-stimulating factor</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Cytotoxicity</subject><subject>Docetaxel</subject><subject>Drug approval</subject><subject>Drug dosages</subject><subject>Drug interaction</subject><subject>Drug interactions</subject><subject>Drug therapy</subject><subject>Drug therapy, Combination</subject><subject>Drugs</subject><subject>Evaluation</subject><subject>Food</subject><subject>Granulocyte colony-stimulating factor</subject><subject>Health insurance</subject><subject>Immunotherapy</subject><subject>Insurance</subject><subject>Leukocytes (granulocytic)</subject><subject>Matching</subject><subject>Medical diagnosis</subject><subject>Medicine and Health Sciences</subject><subject>Neutropenia</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pharmacovigilance</subject><subject>Prescription drugs</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Safety and security measures</subject><subject>Social Sciences</subject><subject>Statistical analysis</subject><subject>Surgery</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk21r2zAQx83YWLtu32BshsHYXiTTg23Zr0bpngKFwp7eirN8ShQUK5Xkrfv2UxK3xKMvhkAyp9_9z3e6y7LnlMwpF_Td2g2-Bzvfuh7nhNWC1-xBdkobzmYVI_zh0fdJ9iSENSElr6vqcXbCBWeCcXGawQc_LGe7LTd9RA8qGteH3Om8cwoj3KBNN_kWosE-hvy3iau89Qgh5gp6hT5vIWCXuz5xYfA7W64smE3IO4jwNHukwQZ8Np5n2Y9PH79ffJldXn1eXJxfzlRVsDhD1grGQGmu27opCt5Bg2WrhK45EsoLVXe8Qs0qXSBHTTRw4ASw4FwTVfOz7OVBd2tdkGN1gmQ1qwQRKfVELA5E52Att95swP-RDozcG5xfSvDRKIuyLaDFkmBTV11BOtIIWnRYV03ZUib20d6P0YZ2g51KtfFgJ6LTm96s5NL9kpQwURa8TApvRgXvrgcMUW5MUGgt9OiG_Y8LVvKmoQl99Q96f3ojtYSUgem1S4HVTlSei5LThoq6StT8HiqtDjdGpV7SJtknDm8nDomJeBOXMIQgF9--_j979XPKvj5iVwg2roKzw77_pmBxAJV3IXjUd1WmRO5G4bYacjcKchyF5Pbi-IXunG57n_8FzNYEYQ</recordid><startdate>20230616</startdate><enddate>20230616</enddate><creator>Shin, Kwang-Hee</creator><creator>Ah, Young-Mi</creator><creator>Cha, Sang Hun</creator><creator>Choi, Hye Duck</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2292-6827</orcidid></search><sort><creationdate>20230616</creationdate><title>Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data</title><author>Shin, Kwang-Hee ; Ah, Young-Mi ; Cha, Sang Hun ; Choi, Hye Duck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642t-e2b722acf3fb89443da9e5bc7f83e0134c8d36ef26f4e3ef0fa3a30ae433f0c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Biology and Life Sciences</topic><topic>Breast cancer</topic><topic>Cancer patients</topic><topic>Care and treatment</topic><topic>Colony-stimulating factor</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Cytotoxicity</topic><topic>Docetaxel</topic><topic>Drug approval</topic><topic>Drug dosages</topic><topic>Drug interaction</topic><topic>Drug interactions</topic><topic>Drug therapy</topic><topic>Drug therapy, Combination</topic><topic>Drugs</topic><topic>Evaluation</topic><topic>Food</topic><topic>Granulocyte colony-stimulating factor</topic><topic>Health insurance</topic><topic>Immunotherapy</topic><topic>Insurance</topic><topic>Leukocytes (granulocytic)</topic><topic>Matching</topic><topic>Medical diagnosis</topic><topic>Medicine and Health Sciences</topic><topic>Neutropenia</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pharmacovigilance</topic><topic>Prescription drugs</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Safety and security measures</topic><topic>Social Sciences</topic><topic>Statistical analysis</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Kwang-Hee</creatorcontrib><creatorcontrib>Ah, Young-Mi</creatorcontrib><creatorcontrib>Cha, Sang Hun</creatorcontrib><creatorcontrib>Choi, Hye Duck</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale in Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Kwang-Hee</au><au>Ah, Young-Mi</au><au>Cha, Sang Hun</au><au>Choi, Hye Duck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-06-16</date><risdate>2023</risdate><volume>18</volume><issue>6</issue><spage>e0287382</spage><epage>e0287382</epage><pages>e0287382-e0287382</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>37327237</pmid><doi>10.1371/journal.pone.0287382</doi><tpages>e0287382</tpages><orcidid>https://orcid.org/0000-0003-2292-6827</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-06, Vol.18 (6), p.e0287382-e0287382 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2826707053 |
| source | PLoS (Open access); Full-Text Journals in Chemistry (Open access); DOAJ Directory of Open Access Journals; PubMed Central; EZB Electronic Journals Library |
| subjects | Age Antimitotic agents Antineoplastic agents Antineoplastic drugs Antitumor agents Biology and Life Sciences Breast cancer Cancer patients Care and treatment Colony-stimulating factor Comorbidity Complications and side effects Cytotoxicity Docetaxel Drug approval Drug dosages Drug interaction Drug interactions Drug therapy Drug therapy, Combination Drugs Evaluation Food Granulocyte colony-stimulating factor Health insurance Immunotherapy Insurance Leukocytes (granulocytic) Matching Medical diagnosis Medicine and Health Sciences Neutropenia Patient outcomes Patients Pharmacovigilance Prescription drugs Regression analysis Regression models Safety and security measures Social Sciences Statistical analysis Surgery |
| title | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A59%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug-Drug%20interactions%20of%20docetaxel%20in%20patients%20with%20breast%20cancer%20based%20on%20insurance%20claims%20data&rft.jtitle=PloS%20one&rft.au=Shin,%20Kwang-Hee&rft.date=2023-06-16&rft.volume=18&rft.issue=6&rft.spage=e0287382&rft.epage=e0287382&rft.pages=e0287382-e0287382&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0287382&rft_dat=%3Cgale_plos_%3EA753191786%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2826707053&rft_id=info:pmid/37327237&rft_galeid=A753191786&rft_doaj_id=oai_doaj_org_article_b4abe50e986d40d09714de8695b127c8&rfr_iscdi=true |